title: Providing Appropriate Risk Information on Genome Editing for Patients.
abstract: Genome editing, represented by CRISPR/Cas9, facilitates somatic and germline gene modifications in many species, including humans. However, one of key issues, off-target mutation deserves special consideration prior to clinical applications. We herein discuss the importance of risk information on genome editing for obtaining legitimate patient consent and social acceptance.
authors.affiliation: Office of Health and Safety, Hokkaido University, Sapporo Hokkaido, 060-0808, Japan.
authors.forename: Motoko
authors.initials: M
authors.lastname: Araki
authors.affiliation: Office of Health and Safety, Hokkaido University, Sapporo Hokkaido, 060-0808, Japan. Electronic address: tishii@general.hokudai.ac.jp.
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Ishii
mesh_terms: D064112:Clustered Regularly Interspaced Short Palindromic Repeats; D018390:Gene Targeting / Q000379:methods*; D015316:Genetic Therapy / Q000009:adverse effects* / Q000379:methods*; D015894:Genome, Human; D006801:Humans; D009154:Mutation; D010342:Patient Acceptance of Health Care; D012306:Risk
keywords: CRISPR/Cas9; clinical application; genome editing; informed consent; off-target mutation; society